141 related articles for article (PubMed ID: 22644027)
1. Anidulafungin for Candida glabrata infective endocarditis.
De Rosa FG; D'Avolio A; Corcione S; Baietto L; Raviolo S; Centofanti P; Pasero D; Rinaldi M; Di Perri G
Antimicrob Agents Chemother; 2012 Aug; 56(8):4552-3. PubMed ID: 22644027
[No Abstract] [Full Text] [Related]
2. Infectious endocarditis caused by Candida glabrata: evidence of in vivo development of echinocandin resistance.
Agnelli C; Guinea J; Valerio M; Escribano P; Bouza E; Muñoz P
Rev Esp Quimioter; 2019 Aug; 32(4):395-397. PubMed ID: 31327188
[No Abstract] [Full Text] [Related]
3. Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata.
Corcione S; D'Avolio A; Pasero D; Trentalange A; Pagani N; Sanguinetti M; De Rosa FG
Infez Med; 2019 Sep; 27(3):328-331. PubMed ID: 31545778
[TBL] [Abstract][Full Text] [Related]
4. FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.
Costa-de-Oliveira S; Marcos Miranda I; Silva RM; Pinto E Silva A; Rocha R; Amorim A; Gonçalves Rodrigues A; Pina-Vaz C
Antimicrob Agents Chemother; 2011 Mar; 55(3):1312-4. PubMed ID: 21149621
[TBL] [Abstract][Full Text] [Related]
5. Cure of Candida glabrata native tricuspid valve endocarditis by continuous infusion of conventional amphotericin B in a patient with nephrotic syndrome.
Williams J; Lye DC
Int J Antimicrob Agents; 2007 Aug; 30(2):192-3. PubMed ID: 17555946
[No Abstract] [Full Text] [Related]
6. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata.
Spreghini E; Orlando F; Sanguinetti M; Posteraro B; Giannini D; Manso E; Barchiesi F
Antimicrob Agents Chemother; 2012 Mar; 56(3):1215-22. PubMed ID: 22203604
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts.
Howard SJ; Livermore J; Sharp A; Goodwin J; Gregson L; Alastruey-Izquierdo A; Perlin DS; Warn PA; Hope WW
Antimicrob Agents Chemother; 2011 Oct; 55(10):4880-7. PubMed ID: 21807969
[TBL] [Abstract][Full Text] [Related]
8. Breakthrough fungemia due to Candida glabrata during posaconazole prophylaxis in hematology patients treated with anidulafungin - report of 5 cases.
Krcmery V; Demitrovicova A; Kisac P
J Chemother; 2011 Oct; 23(5):310-1. PubMed ID: 22005067
[No Abstract] [Full Text] [Related]
9. Differential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.
Arendrup MC; Perlin DS; Jensen RH; Howard SJ; Goodwin J; Hope W
Antimicrob Agents Chemother; 2012 May; 56(5):2435-42. PubMed ID: 22354305
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic study of anidulafungin in ICU patients with intra-abdominal candidiasis.
Dupont H; Massias L; Jung B; Ammenouche N; Montravers P
J Antimicrob Chemother; 2017 May; 72(5):1429-1432. PubMed ID: 28088767
[TBL] [Abstract][Full Text] [Related]
11. Hampered by historical paradigms--echinocandins and the treatment of Candida endocarditis.
Gardiner BJ; Slavin MA; Korman TM; Stuart RL
Mycoses; 2014 May; 57(5):316-9. PubMed ID: 24251958
[TBL] [Abstract][Full Text] [Related]
12. Candida glabrata and FKS mutations: witnessing the emergence of the true multidrug-resistant Candida.
Ostrosky-Zeichner L
Clin Infect Dis; 2013 Jun; 56(12):1733-4. PubMed ID: 23487384
[No Abstract] [Full Text] [Related]
13. Micafungin therapy in a critically ill, morbidly obese patient.
Zomp A; Bookstaver PB; Ahmed Y; Turner JE; King C
J Antimicrob Chemother; 2011 Nov; 66(11):2678-80. PubMed ID: 21810839
[No Abstract] [Full Text] [Related]
14. Endocarditis caused by Candida dubliniensis.
Garcia J; Soch K; Matthew E; Surani S; Horseman MA
Am J Med Sci; 2013 Sep; 346(3):237-9. PubMed ID: 23974269
[TBL] [Abstract][Full Text] [Related]
15. Candida dubliniensis in recurrent polymicrobial tricuspid endocarditis.
Tran C; Cometta A; Letovanec I; Jaton K; Wenger A; Ruchat P; Jaussi A
Echocardiography; 2007 Aug; 24(7):756-9. PubMed ID: 17651106
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamic modelling of anidulafungin against Candida spp.
Gil-Alonso S; Jauregizar N; Ortega I; Eraso E; Suárez E; Quindós G
Int J Antimicrob Agents; 2016 Mar; 47(3):178-83. PubMed ID: 26857078
[TBL] [Abstract][Full Text] [Related]
17. EUCAST Reference Testing of Rezafungin Susceptibility and Impact of Choice of Plastic Plates.
Arendrup MC; Jørgensen KM; Hare RK; Cuenca-Estrella M; Zaragoza O
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285230
[TBL] [Abstract][Full Text] [Related]
18.
Bordallo-Cardona MÁ; Agnelli C; Gómez-Nuñez A; Sánchez-Carrillo C; Bouza E; Muñoz P; Escribano P; Guinea J
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30397068
[TBL] [Abstract][Full Text] [Related]
19. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.
Cleary JD; Garcia-Effron G; Chapman SW; Perlin DS
Antimicrob Agents Chemother; 2008 Jun; 52(6):2263-5. PubMed ID: 18378714
[TBL] [Abstract][Full Text] [Related]
20. Native valve endocarditis due to Candida glabrata treated without valvular replacement: a potential role for caspofungin in the induction and maintenance treatment.
Jiménez-Expósito MJ; Torres G; Baraldés A; Benito N; Marco F; Paré JC; Moreno A; Claramonte X; Mestres CA; Almela M; García de la María C; Pérez N; Schell WA; Corey GR; Perfect J; Jiménez de Anta MT; Gatell JM; Miró JM
Clin Infect Dis; 2004 Oct; 39(7):e70-3. PubMed ID: 15472836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
